Key Takeaways
- • Health Wildcatters unveiled its 14th cohort comprising 10 innovative healthcare startups spanning the U.S., Canada, and Israel, with one-third female-founded or female-led, addressing gaps in drug discovery, diagnostics, hospital operations, and chronic disease management.
- • The cohort spans six critical healthcare verticals: AI-powered drug discovery (Atomistic Insights), saliva-based diagnostics for fatty liver disease (Calaris Diagnostics), hospital discharge automation (DISCHARGEpath), AI workforce optimization (EquiShift), international nursing recruitment (Full Time Nurse Staffing Inc.), and medical devices for glaucoma and lymphedema.
- • INVEST Digital Health conference, scheduled for October 29 at Pegasus Park in Dallas, will feature Health Wildcatters co-founder and CEO Dr. Hubert Zajicek moderating a panel on consumer-centric convenience reshaping clinical strategy, with panelists including executives from Novellia, Kin Health, and Reperio Health.
- • The 2026 cohort collectively targets healthcare's highest-friction points: clinician burnout and workforce allocation inefficiency, post-acute care coordination complexity, clinical trial participant retention barriers, and therapeutic gaps in pain management and chronic lymphatic conditions.
- • Health Wildcatters positioning itself as a hub within North Texas's rapidly expanding healthcare innovation ecosystem, leveraging Pegasus Park as both an accelerator base and conference venue to attract institutional capital and industry partnerships.
Summary
Health Wildcatters, the Dallas-based healthcare accelerator and MedCity News partner, has selected its 14th cohort of 10 startups representing a geographically diverse pool across the U.S., Canada, and Israel. The 2026 cohort demonstrates strong female leadership representation, with one-third of companies either female-founded or female-led, reflecting broader institutional commitments to founder diversity in healthtech venture capital.
The portfolio spans multiple healthcare subsectors with distinct market opportunities. Atomistic Insights leverages physics-guided artificial intelligence to accelerate drug discovery through its proprietary DeepPath platform, addressing the historically lengthy and costly protein dynamics analysis phase. Calaris Diagnostics is developing saliva-based diagnostic technologies for early detection of metabolic-associated fatty liver disease (MASLD/MASH), a significant unmet diagnostic need given rising prevalence rates. DISCHARGEpath targets hospital operational inefficiency through an agentic AI platform automating discharge coordination—encompassing eligibility verification, prior authorization, post-acute placement, and remote monitoring—representing a substantial revenue recapture opportunity for health systems. EquiShift addresses clinician burnout through AI-powered demand forecasting and shift-specific staffing recommendations, directly targeting workforce optimization costs and retention challenges. Full Time Nurse Staffing Inc. tackles the acute U.S. nursing shortage through international recruitment and training infrastructure.
On the specialized medicine and devices front, MG Health Tech combines AI, sensors, and connectivity infrastructure for real-time, data-driven clinical care. PatientX offers real-time feedback analytics for clinical trial participants, addressing trial retention barriers—a critical bottleneck in pharmaceutical development timelines. SanaOculis is developing a non-invasive neurostimulation device for glaucoma progression, while Sub-Q Bionics is engineering a fully implantable bionic lymphatic drainage system for lymphedema management. Venom Biologics is pursuing non-opioid chronic pain treatments through engineered peptides targeting sodium channels in pain-sensing neurons.
Health Wildcatters co-founder and CEO Dr. Hubert Zajicek will moderate a panel discussion at the October 29 INVEST Digital Health conference focused on how consumer-centric convenience is reshaping clinical strategy and driving improved patient loyalty, adherence, and outcomes. The panel will include Angeline Chen (Novellia Founding Director of Product), Arpan Parikh (Kin Health CEO), and Travis Rush (Reperio Health CEO). Zajicek characterized the cohort as positioned to "address some of healthcare's most complex challenges and shape the future of care" over the coming years, signaling institutional expectations for portfolio company trajectory and exit multiples.
The portfolio spans multiple healthcare subsectors with distinct market opportunities. Atomistic Insights leverages physics-guided artificial intelligence to accelerate drug discovery through its proprietary DeepPath platform, addressing the historically lengthy and costly protein dynamics analysis phase. Calaris Diagnostics is developing saliva-based diagnostic technologies for early detection of metabolic-associated fatty liver disease (MASLD/MASH), a significant unmet diagnostic need given rising prevalence rates. DISCHARGEpath targets hospital operational inefficiency through an agentic AI platform automating discharge coordination—encompassing eligibility verification, prior authorization, post-acute placement, and remote monitoring—representing a substantial revenue recapture opportunity for health systems. EquiShift addresses clinician burnout through AI-powered demand forecasting and shift-specific staffing recommendations, directly targeting workforce optimization costs and retention challenges. Full Time Nurse Staffing Inc. tackles the acute U.S. nursing shortage through international recruitment and training infrastructure.
On the specialized medicine and devices front, MG Health Tech combines AI, sensors, and connectivity infrastructure for real-time, data-driven clinical care. PatientX offers real-time feedback analytics for clinical trial participants, addressing trial retention barriers—a critical bottleneck in pharmaceutical development timelines. SanaOculis is developing a non-invasive neurostimulation device for glaucoma progression, while Sub-Q Bionics is engineering a fully implantable bionic lymphatic drainage system for lymphedema management. Venom Biologics is pursuing non-opioid chronic pain treatments through engineered peptides targeting sodium channels in pain-sensing neurons.
Health Wildcatters co-founder and CEO Dr. Hubert Zajicek will moderate a panel discussion at the October 29 INVEST Digital Health conference focused on how consumer-centric convenience is reshaping clinical strategy and driving improved patient loyalty, adherence, and outcomes. The panel will include Angeline Chen (Novellia Founding Director of Product), Arpan Parikh (Kin Health CEO), and Travis Rush (Reperio Health CEO). Zajicek characterized the cohort as positioned to "address some of healthcare's most complex challenges and shape the future of care" over the coming years, signaling institutional expectations for portfolio company trajectory and exit multiples.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.